'Antithrombotic Drug Market Will Reach $24.3 Billion in 2015' Shows new Visiongain Report
* Reuters is not responsible for the content in this press release.
'Antithrombotic Drug Market Will Reach $24.3 Billion in 2015' Shows new Visiongain Report LONDON, February 16, 2013 /PRNewswire/ -- A new report by Visiongain [http://www.visiongain.com ] predicts that the world antithrombotic drug market [http://www.visiongain.com/Sector/8/Pharma ] will reach revenue of $24.3 billion in 2015. That pharma market generated $22.7 billion in 2011, according to Antithrombotic Drugs: World Market 2013-2023 [http://www.visiongain.com/Report/982/Antithrombotic-Drugs-World-Market-2013-2023 ], published in February 2013. Visiongain is a business information provider based in London, UK. That study shows the overall market for antithrombotic drugs will expand steadily from 2013 to 2023. This expansion is due to rising disease prevalence and increases in healthcare spending in developing countries. The strength of the antithrombotic drug market stems from the high profile of the conditions associated with thrombotic disease, which require long term drug treatment, generating a high volume of long-term drug sales. That market holds great promise, for existing drugs and products under development. Jennifer Taylor, a pharmaceutical industry analyst in visiongain, said: "The antithrombotic drug market is currently suffering from the loss of patent protection of the two leading drugs, Plavix and Lovenox. However, the market will soon recover with the establishment of novel oral anticoagulants on the market. Eliquis has recently received FDA approval and will soon capture a predominant share of the novel oral anticoagulant market. One major unmet need driving the antithrombotic drug market is that of an antidote for these novel oral anticoagulants. There are several antidotes in the R&D pipeline; when approved, those agents can look forward to a share of a $2 billion submarket. "The establishment of those novel oral anticoagulants will change the face of the antithrombotic drug market. Currently, platelet aggregation inhibitors are the leading therapeutic class. However, the rapid growth in revenue of the direct thrombin inhibitor and direct factor Xa inhibitor therapeutic subclasses means anticoagulant drugs will become the leading group in that market within our forecast period." Visiongain's report shows revenue forecasts to 2023 at overall world market, submarket, product and national level. It forecasts the world-level submarkets of platelet aggregation inhibitors, anticoagulants and fibrinolytics. The study also forecasts the main subclasses of anticoagulant drug: - Heparins - Vitamin K antagonists - Direct thrombin inhibitors - Direct factor Xa inhibitors. To 2023, the report forecasts revenues of leading products, including Plavix, Lovenox, Pradaxa, Pletal and Aggrenox, as well as sales of newer drugs - Effient, Brilinta, Xarelto and Eliquis. The work also forecasts national markets to 2023: the US, Japan, Germany, France, Italy, the UK, Spain (EU5), Brazil, Russia, India and China (BRIC). Other analyses include a review of R&D and research interviews with authorities in academia, medicine and industry. Antithrombotic Drugs: World Market 2013-2023 adds to visiongain's range of analytical reports on industries and markets in healthcare. For sample pages and further information concerning Visiongain report the Antithrombotic Drugs: World Market 2013-2023 please visit: http://www.visiongain.com/Report/982/Antithrombotic-Drugs-World-Market-2013-2023 For an executive summary please contact: Sara Peerun firstname.lastname@example.org or Tel: +44 (0) 20 7336 6100 Companies Listed Ablynx Alchemia Alchemix American Heart Association (AHA) Amphastar Pharmaceuticals ARCA Biopharma Armetheon Inc. ARYx Therapeutics Asahi Kasei Pharma America AstraZeneca Barr Pharmaceuticals Bayer Baylor College of Medicine Bharat Biotech BioVascular Boehringer Ingelheim Bristol-Myers Squibb Canyon Pharmaceuticals Centers for Disease Control and Prevention (CDC) D. Western Therapeutics Institute Daiichi Sankyo Dr. Reddy's Laboratories Eli Lilly Endotis Pharma European Medicines Agency (EMA) Food and Drug Administration (US FDA) Gate Pharmaceuticals Genentech GlaxoSmithKline Grifols Therapeutics ISIS Pharmaceuticals Johnson & Johnson Kowa Kyowa Hakko LG Life Sciences LIMES Institute Lundbeck Merck & Co. Mitsubishi Kasei Momenta Pharmaceuticals Mount Sinai School of Medicine Mylan Pharmaceuticals National Health Service (NHS) National Institute for Clinical Excellence (NICE) Novartis Organon Otsuka Pharmaceutical Company Pfizer Pharmacyclics PLx Pharma Polymedix Portola Pharmaceuticals Pozen Regado Biosciences Roche Sandoz (part of Novartis) Sanofi Teva Pharmaceutical Industries The Medicines Company The Mount Sinai Medical Center ThromboGenics University of Insubria Virginia Commonwealth University Watson Pharmaceuticals World Health Organization (WHO) Zena and Michael A. Wiener Cardiovascular Institute About visiongain Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44(0)207-336-6100 Visiongain
- Putin dissolves state news agency, tightens grip on Russia media
- North Korea says Kim's powerful uncle dismissed for 'criminal acts'
- Cold, ice grip U.S. as more snow to blanket East
- Thai PM calls snap election, protesters want power now |
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'